Do I need a prescription for Nadolol 10mg/5ml oral solution?

Nadolol 10mg/5ml oral solution is classified as a Valid as a prescribable product in the UK. However, always consult a pharmacist or doctor before use. (Source: NHS dm+d)

What are the brand names for Nadolol 10mg/5ml oral solution?

Nadolol 10mg/5ml oral solution is the generic name. It is available under brand names including: Nadolol 10mg/5ml oral solution. (Source: NHS dm+d — Actual Medicinal Products)

Nadolol 10mg/5ml oral solution

Prescription only

Requires a prescription from a doctor or prescriber

Oral solution

10mg/5ml

Oral

Antihypertensive

Unlicensed beta-blocker

Beta-adrenoceptor blocking drugs

Active ingredients:

Nadolol

BNF classificationBrowse formulary

Where this medicine sits in the British National Formulary — the UK's standard prescribing reference

BNF 02.04

ATC classificationBrowse ATC index

International classification by the WHO, grouping medicines by the organ system they act on

ATC C07AA12

Chemical classBrowse classes

Classification based on the molecule's chemical structure and properties

Primary care groupBrowse groups

NHS medication clusters used to compare prescribing patterns across GP practices

Antihypertensive

Unlicensed beta-blocker

Check interactions for Nadolol

No active safety alerts

Official documents, adverse reaction reporting, and safety monitoring

Report a side effect

Submit a Yellow Card report to the MHRA

Official medicine documents

Yellow Card

Report side effects (MHRA)

Drug safety updates

MHRA alerts for Nadolol

Source: MHRA Products DatabaseOGL 3.0

Updated 3 months ago(16 Jan 2026)

Safety monitoring data

Yellow Card reports

MHRA

The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.

View Drug Analysis Profile

Suspected adverse reactions reported for Nadolol

Browse all iDAP reports

Interactive Drug Analysis Profiles for all medicines

Report a side effect

Submit a Yellow Card report to the MHRA

Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.

EudraVigilance

EMA

The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.

View EudraVigilance report

Suspected adverse reactions reported for Nadolol

About EudraVigilance

Learn about EU pharmacovigilance and safety monitoring

EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.

1 branded products available

1 productsShow details

1 products

Possibly available on the UK marketRestricted supplyDiscontinuedAvailability per NHS dm+d

MHRA licensed products

View all licensed products for Nadolol on the MHRA register

Nadolol 10mg/5ml oral solution

Special Order

None

Special

Source: NHS dm+dOGL 3.0

Updated about 1 month ago(1 Mar 2026)

Daily doseShow details

WHO defined daily dose (DDD)

160 mg

Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.

Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via NHS dm+d BNF mapping files. Contains public sector information licensed under the Open Government Licence v3.0.

Therapeutically similar medicines

10 similarShow details

Sotalol 50mg/5ml oral suspension

Oral suspension

50mg/5ml

Same therapeutic group

Nadolol 100mg/5ml oral suspension

Oral suspension

100mg/5ml

Same therapeutic group

Nadolol 25mg/5ml oral solution

Oral solution

25mg/5ml

Same therapeutic group

Nadolol 10mg/5ml oral suspension

Oral suspension

10mg/5ml

Same therapeutic group

Nadolol 20mg/5ml oral solution

Oral solution

20mg/5ml

Same therapeutic group

Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.

NHS prescribing volume and spending trends

Show details

Loading prescribing data...

Clinical guidelines and formulary information

British National Formulary

Nadolol

BNF

Drug monograph — bnf.nice.org.uk

Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.

Check stock at pharmacies and supply information

Show details

Pharmacy stock checkers

Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.

Boots

Search products

Click & collectNHS

Lloyds

Search products

DeliveryNHS

P2U

Pharmacy2U

Search products

DeliveryNHS

Supply & product information

Official product databases and supply status monitoring

Shortages info

NHS Specialist Pharmacy Service (SPS)

emc product search

Discontinuations & alternatives for Nadolol

Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.

Codes for healthcare professionals and prescribing systems

Show details

These codes are used by healthcare IT systems and prescribers to identify this medicine.

NHS UK identifiers

SNOMED CT

27890211000001107

dm+d ID

27890211000001107

VTM (Virtual Therapeutic Moiety)

776851004

VMP (Virtual Medicinal Product)

27890211000001107

BNF code

02040000

International identifiers

ATC code — Anatomical Therapeutic Chemical (WHO)

C07AA12

Browse tools

dm+d Browser

NHSBSA medicines dictionary lookup

SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).

Active and completed clinical studies from ClinicalTrials.gov

Show details

Searching UK clinical trials...

Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.

Pharmacology and chemical data from DrugBank

go.drugbank.com

Key facts

Drug status

Approved

Major interactions

10 found

Half-life

20 to 24 hours

Mechanism

Although nadolol is described as a non selective beta blocker, it does not interact with beta 3 adrenal receptors.

Food interactions

3 warnings

Human targets

2 targets

Data: DrugBank · CC BY-NC 4.0

Pharmacokinetics at a glance

Absorption

30%

Oral doses of nadolol are approximately 30% absorbed.
[L7922][L7925]
In healthy subjects, nadolol has a T_max of 2.7h…

Half-life

20 to 24 hours

The half life of nadolol is 20 to 24 hours.
[L7922][L7925]

Protein binding

30%

Nadolol is approximately 30% bound to plasma protein.
[L7922][L7925]
Nadolol binds to alpha-1-acid glycoprotein in plasma.
[A182366][A182372]

Volume of distribution

147-157L

In healthy subjects, the volume of distribution of nadolol is 147-157L.
[A182423]

Metabolism

Nadolol is not metabolized by the liver in humans.
[A182423][L7922][L7925]

Elimination

60%

Nadolol is not metabolized in the liver and excreted mainly in the urine.
[L7922][L7925]…

Clearance

219-250mL/min

In healthy subjects, the total body clearance of nadolol is 219-250mL/min and the renal clearance is 131-150mL/min.
[A182423]

Pharmacokinetic data: DrugBank · CC BY-NC 4.0

Status:

Approved

Investigational

Small molecule

About this compound

Nadolol is a nonselective beta adrenal receptor blocker that is used to lower blood pressure.[L7922][L7925] Nonselective beta adrenal receptor blockers may no longer be first line in the treatment of hypertension as newer generations of beta adrenal receptor blockers have higher selectivity and offer better rates of adverse effects.[A34177]

Nadolol was granted FDA approval on 10 December 1979.[L7922]

Properties:

solid

Avg. mass: 309.40 Da

DrugBank indication

Nadolol is indicated to treat angina pectoris and hypertension.
[L7922]
Another product formulated with [bendroflumethiazide] is indicated to treat hypertension.
[L7925]

Also known as(46)

Nadolol

ADRB1R

B1AR

Beta-1 adrenoceptor

Beta-1 adrenoreceptor

ADRB2R

B2AR

Beta-2 adrenoceptor

Dosage forms(11)

Tablet (Oral) — 160 mg

Tablet (Oral)

Tablet (Oral) — 120 mg/1

Tablet (Oral)

Tablet (Oral) — 160 mg/1

Tablet (Oral) — 20 mg/1

Tablet (Oral) — 40 mg/1

Tablet (Oral) — 80 mg/1

Molecular properties(19)

Drug interactions(1702)

Known interactions with other medications. Always consult a healthcare professional.

Duloxetine

Major

DB00476

The risk or severity of orthostatic hypotension and syncope can be increased when Nadolol is combined with Duloxetine.

Check this interaction

Levodopa

Major

DB01235

The risk or severity of hypotension and orthostatic hypotension can be increased when Nadolol is combined with Levodopa.

Check this interaction

Risperidone

Moderate

DB00734

Nadolol may increase the hypotensive activities of Risperidone.

Check this interaction

Ceritinib

Moderate

DB09063

Nadolol may increase the bradycardic activities of Ceritinib.

Check this interaction

Ivabradine

Moderate

DB09083

Nadolol may increase the bradycardic activities of Ivabradine.

Check this interaction

Ruxolitinib

Moderate

DB08877

Ruxolitinib may increase the bradycardic activities of Nadolol.

Check this interaction

Alfuzosin

Moderate

DB00346

Alfuzosin may increase the hypotensive activities of Nadolol.

Check this interaction

Amifostine

Moderate

DB01143

Nadolol may increase the hypotensive activities of Amifostine.

Check this interaction

Diazoxide

Moderate

DB01119

Diazoxide may increase the hypotensive activities of Nadolol.

Check this interaction

Methylphenidate

Moderate

DB00422

Methylphenidate may decrease the antihypertensive activities of Nadolol.

Check this interaction

Dexmethylphenidate

Moderate

DB06701

Dexmethylphenidate may decrease the antihypertensive activities of Nadolol.

Check this interaction

Obinutuzumab

Moderate

DB08935

Nadolol may increase the hypotensive activities of Obinutuzumab.

Check this interaction

Pentoxifylline

Moderate

DB00806

Pentoxifylline may increase the hypotensive activities of Nadolol.

Check this interaction

Rituximab

Moderate

DB00073

Nadolol may increase the hypotensive activities of Rituximab.

Check this interaction

Zolmitriptan

Moderate

DB00315

Zolmitriptan may decrease the antihypertensive activities of Nadolol.

Check this interaction

Doxapram

Moderate

DB00561

Doxapram may decrease the antihypertensive activities of Nadolol.

Check this interaction

Phenmetrazine

Moderate

DB00830

Phenmetrazine may decrease the antihypertensive activities of Nadolol.

Check this interaction

Naratriptan

Moderate

DB00952

Naratriptan may decrease the antihypertensive activities of Nadolol.

Check this interaction

Frovatriptan

Moderate

DB00998

Frovatriptan may decrease the antihypertensive activities of Nadolol.

Check this interaction

Dutasteride

Moderate

DB01126

Dutasteride may decrease the antihypertensive activities of Nadolol.

Check this interaction

Finasteride

Moderate

DB01216

Finasteride may decrease the antihypertensive activities of Nadolol.

Check this interaction

Solifenacin

Moderate

DB01591

Solifenacin may decrease the antihypertensive activities of Nadolol.

Check this interaction

Epicaptopril

Moderate

DB02032

Epicaptopril may decrease the antihypertensive activities of Nadolol.

Check this interaction

1-benzylimidazole

Moderate

DB04581

1-benzylimidazole may decrease the antihypertensive activities of Nadolol.

Check this interaction

Amineptine

Moderate

DB04836

Amineptine may decrease the antihypertensive activities of Nadolol.

Check this interaction

Naluzotan

Moderate

DB05562

Naluzotan may decrease the antihypertensive activities of Nadolol.

Check this interaction

Nitrous oxide

Moderate

DB06690

Nitrous oxide may decrease the antihypertensive activities of Nadolol.

Check this interaction

Cinitapride

Moderate

DB08810

Cinitapride may decrease the antihypertensive activities of Nadolol.

Check this interaction

Lurasidone

Moderate

DB08815

Lurasidone may decrease the antihypertensive activities of Nadolol.

Check this interaction

Tyramine

Moderate

DB08841

Tyramine may decrease the antihypertensive activities of Nadolol.

Check this interaction

Ifenprodil

Moderate

DB08954

Ifenprodil may decrease the antihypertensive activities of Nadolol.

Check this interaction

Butriptyline

Moderate

DB09016

Butriptyline may decrease the antihypertensive activities of Nadolol.

Check this interaction

Tianeptine

Moderate

DB09289

Tianeptine may decrease the antihypertensive activities of Nadolol.

Check this interaction

Oxaprotiline

Moderate

DB09307

Oxaprotiline may decrease the antihypertensive activities of Nadolol.

Check this interaction

Atipamezole

Moderate

DB11481

Atipamezole may decrease the antihypertensive activities of Nadolol.

Check this interaction

Tetrahydrocannabivarin

Moderate

DB11755

Tetrahydrocannabivarin may decrease the antihypertensive activities of Nadolol.

Check this interaction

Piclozotan

Moderate

DB12361

Piclozotan may decrease the antihypertensive activities of Nadolol.

Check this interaction

Siponimod

Moderate

DB12371

Siponimod may decrease the antihypertensive activities of Nadolol.

Check this interaction

Idazoxan

Moderate

DB12551

Idazoxan may decrease the antihypertensive activities of Nadolol.

Check this interaction

Tramazoline

Moderate

DB13064

Tramazoline may decrease the antihypertensive activities of Nadolol.

Check this interaction

Amitriptylinoxide

Moderate

DB13114

Amitriptylinoxide may decrease the antihypertensive activities of Nadolol.

Check this interaction

Dibenzepin

Moderate

DB13225

Dibenzepin may decrease the antihypertensive activities of Nadolol.

Check this interaction

Quinupramine

Moderate

DB13246

Quinupramine may decrease the antihypertensive activities of Nadolol.

Check this interaction

Trichloroethylene

Moderate

DB13323

Trichloroethylene may decrease the antihypertensive activities of Nadolol.

Check this interaction

Fenozolone

Moderate

DB13341

Fenozolone may decrease the antihypertensive activities of Nadolol.

Check this interaction

Melitracen

Moderate

DB13384

Melitracen may decrease the antihypertensive activities of Nadolol.

Check this interaction

Lofepramine

Moderate

DB13411

Lofepramine may decrease the antihypertensive activities of Nadolol.

Check this interaction

Xenon

Moderate

DB13453

Xenon may decrease the antihypertensive activities of Nadolol.

Check this interaction

Iprindole

Moderate

DB13496

Iprindole may decrease the antihypertensive activities of Nadolol.

Check this interaction

Buflomedil

Moderate

DB13510

Buflomedil may decrease the antihypertensive activities of Nadolol.

Check this interaction

Showing 50 of 1702 interactions

Food & lifestyle interactions

Avoid Alcohol

Avoid alcohol.

Advice

Avoid natural licorice.

Advice

Take with or without food. The absorption is unaffected by food.

Toxicity & overdose

The oral LD₅₀ in mice is 4500mg/kg.
[L7934]

Patients experiencing an overdose may present with bradycardia, cardiac failure, hypotension, and bronchospasm.
[L7922][L7925]
An overdose may be treated with atropine for bradycardia, digitalis and diuretics for cardiac failure, vasopressors for hypotension, and beta-2 stimulants for bronchospasms, as well as gastric lavage and hemodialysis.
[L7922][L7925]

How it works

Mechanism of action

Although nadolol is described as a non selective beta blocker, it does not interact with beta 3 adrenal receptors.[A182402] Antagonism of beta-1 and beta-2 adrenoceptors in the heart inhibits cyclic AMP and its signalling pathway, decreasing the strength and speed of contractions as well as the speed of relaxation and conduction.[A34177] Antagonism of beta-2 adrenoceptors in the smooth muscle cells of the vasculature inhibits their relaxation, leading to an increase in peripheral vascular resistance and reducing the risk of severe hypotension.[A34177] The increase in peripheral vascular resistance may contribute to the decrease in insulin sensitivity associated with nadolol use.[A182441] Antagonism of beta-1 adrenoceptors in the juxtaglomerular apparatus of the kidney inhibits the release of renin, and therefore angiotensin II mediated vasoconstriction, aldosterone mediated water retention, and the release of epinephrine.[A34177] Antagonism of beta-2 adrenoceptors in the liver and skeletal muscle inhibits glycogenolysis, in the lungs prevents bronchodilation, and in the pancrease inhibits insulin release.[A34177]

Pharmacodynamics

Nadolol is a nonselective beta adrenal receptor blocker that is used to lower blood pressure.[L7922][L7925] It has a long duration of action as it is usually taken once daily and a wide therapeutic index as patients start at doses of 40mg daily but may be increased to doses as high as 240mg daily.[L7922][L7925] Patients taking nadolol should not aburptly stop taking it as this may lead to exacerbation of ischemic heart disease.[L7922][L7925]

Pharmacokinetics

How the body processes this drug — absorption, distribution, metabolism, and elimination

Absorption

Oral doses of nadolol are approximately 30% absorbed.
[L7922][L7925]
In healthy subjects, nadolol has a T_max of 2.7h with a C_max or 69±15ng/mL following a 60mg oral dose and 132±27ng/mL after a 120mg oral dose.
[A182417]
The AUC following a 60mg oral dose was 1021ng\*h/mL and following a 120mg oral dose was 1913±382ng\*h/mL.
[A182417]

Half-life

The half life of nadolol is 20 to 24 hours.
[L7922][L7925]

Protein binding

Nadolol is approximately 30% bound to plasma protein.
[L7922][L7925]
Nadolol binds to alpha-1-acid glycoprotein in plasma.
[A182366][A182372]

Volume of distribution

In healthy subjects, the volume of distribution of nadolol is 147-157L.
[A182423]

Metabolism

Nadolol is not metabolized by the liver in humans.
[A182423][L7922][L7925]

Route of elimination

Nadolol is not metabolized in the liver and excreted mainly in the urine.
[L7922][L7925]
In healthy subjects, following intravenous dosing, 60% of a dose is eliminated in the urine and 15% in the feces after 72 hours.
[A182423]
The remainder of the dose is expected to be eliminated in the feces afterwards.
[A182423]

Clearance

In healthy subjects, the total body clearance of nadolol is 219-250mL/min and the renal clearance is 131-150mL/min.
[A182423]

Drug targets(2)

Proteins and enzymes this drug interacts with in the body

Beta-1 adrenergic receptor

BE0000172

ADRB1

antagonist

Specific functionalpha-2A adrenergic receptor binding

Cellular location

Cell membrane

General function & pharmacology

Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.

Involved in the regulation of sleep/wake behaviors PMID:31473062

Beta-2 adrenergic receptor

BE0000694

ADRB2

antagonist

Specific functionadenylate cyclase binding

Cellular location

Cell membrane

General function & pharmacology

Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine

Transporters(5)

Proteins that transport this drug across cell membranes

ATP-dependent translocase ABCB1

BE0001032

ABCB1

substrate

Specific functionABC-type xenobiotic transporter activity

Cellular location

Cell membrane

General function & pharmacology

Translocates drugs and phospholipids across the membrane .
PMID:2897240 PMID:35970996 PMID:8898203 PMID:9038218 PMID:35507548

Catalyzes the flop of phospholipids from the cytoplasmic to the exoplasmic leaflet of the apical membrane. Participates mainly to the flop of phosphatidylcholine, phosphatidylethanolamine, beta-D-glucosylceramides and sphingomyelins .
PMID:8898203
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells PMID:2897240 PMID:35970996 PMID:9038218

POU domain, class 2, transcription factor 1

BE0009712

POU2F1

substrate

Specific functionDNA binding

Cellular location

Nucleus

General function & pharmacology

Transcription factor that binds to the octamer motif (5'-ATTTGCAT-3') and activates the promoters of the genes for some small nuclear RNAs (snRNA) and of genes such as those for histone H2B and immunoglobulins. Modulates transcription transactivation by NR3C1, AR and PGR

POU domain, class 2, transcription factor 2

BE0004865

POU2F2

substrate

Specific functionDNA-binding transcription factor activity

Cellular location

Cytoplasm

General function & pharmacology

Transcription factor that specifically binds to the octamer motif (5'-ATTTGCAT-3') .
PMID:2904654 PMID:7859290
Regulates IL6 expression in B cells with POU2AF1 (By similarity). Regulates transcription in a number of tissues in addition to activating immunoglobulin gene expression .
PMID:2901913 PMID:2904654
Modulates transcription transactivation by NR3C1, AR and PGR PMID:10480874

Multidrug and toxin extrusion protein 1

BE0003657

SLC47A1

substrate

Specific functionantiporter activity

Cellular location

Cell membrane

General function & pharmacology

Multidrug efflux pump that functions as a H(+)/organic cation antiporter .
PMID:16330770 PMID:17509534
Plays a physiological role in the excretion of cationic compounds including endogenous metabolites, drugs, toxins through the kidney and liver, into urine and bile respectively .
PMID:16330770 PMID:17495125 PMID:17509534 PMID:17582384 PMID:18305230 PMID:19158817 PMID:21128598 PMID:24961373

Mediates the efflux of endogenous compounds such as creatinine, vitamin B1/thiamine, agmatine and estrone-3-sulfate .
PMID:16330770 PMID:17495125 PMID:17509534 PMID:17582384 PMID:18305230 PMID:19158817 PMID:21128598 PMID:24961373

May also contribute to regulate the transport of cationic compounds in testis across the blood-testis-barrier (Probable)

Multidrug and toxin extrusion protein 2

BE0004752

SLC47A2

substrate

Specific functionantiporter activity

Cellular location

Cell membrane

General function & pharmacology

Multidrug efflux pump that functions as a H(+)/organic cation antiporter. Mediates the efflux of cationic compounds, such as the model cations, tetraethylammonium (TEA) and 1-methyl-4-phenylpyridinium (MPP+), the platinum-based drug oxaliplatin or weak bases that are positively charged at physiological pH, cimetidine, the platinum-based drugs cisplatin and oxaliplatin or the antidiabetic drug metformin. Mediates the efflux of endogenous compounds such as, creatinine, thiamine and estrone-3-sulfate.

Plays a physiological role in the excretion of drugs, toxins and endogenous metabolites through the kidney

Carriers(1)

Proteins that carry this drug through the body

Alpha-1-acid glycoprotein 2

BE0004879

ORM2

binder

Cellular location

Secreted

General function & pharmacology

Functions as a transport protein in the blood stream. Binds various hydrophobic ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability.

Appears to function in modulating the activity of the immune system during the acute-phase reaction

Biological pathways(1)

Nadolol Action Pathway

Involved compounds

ATP,Calcium,Magnesium cation,Nadolol,Potassium cation

Scientific references(7)

Cernecka H., Sand C., Michel M.C.

The odd sibling: features of beta3-adrenoceptor pharmacology.

Molecular Pharmacology

2014 Nov86(5):479-84. doi: 10.1124/mol.114.092817. Epub 2014 Jun 2

PMID: 24890609 DOI: 10.1124/mol.114.092817

Schafer-Korting M., Bach N., Knauf H., Mutschler E.

Pharmacokinetics of nadolol in healthy subjects.

European Journal of Clinical Pharmacology

198426(1):125-127. doi: 10.1007/bf00546720

PMID: 6714285 DOI: 10.1007/bf00546720

Morrison R.A., Singhvi S.M., Creasey W.A., Willard D.A.

Dose proportionality of nadolol pharmacokinetics after intravenous administration to healthy subjects.

European Journal of Clinical Pharmacology

198833(6):625-628. doi: 10.1007/bf00542499

PMID: 3366166 DOI: 10.1007/bf00542499

Patel L., Johnson A., Turner P.

Nadolol binding to human serum proteins.

Journal Pharmacy Pharmacology

1984 Jun36(6):414-5. doi: 10.1111/j.2042-7158.1984.tb04413.x

PMID: 6146679 DOI: 10.1111/j.2042-7158.1984.tb04413.x

Israili Z.H., Dayton P.G.

Human alpha-1-glycoprotein and its interactions with drugs.

Drug Metabolism Review

2001 May33(2):161-235. doi: 10.1081/DMR-100104402

PMID: 11495502 DOI: 10.1081/DMR-100104402

Lee W.G., Murphy R., McCall J.L., Gane E.J., Soop M., Tura A., Plank L.D.

Nadolol reduces insulin sensitivity in liver cirrhosis: a randomized double-blind crossover trial.

Diabetes Metabolism Research Review

2017 Mar33(3). doi: 10.1002/dmrr.2859. Epub 2016 Nov 10

PMID: 27667324 DOI: 10.1002/dmrr.2859

Gorre F., Vandekerckhove H.

Beta-blockers: focus on mechanism of action.

Which beta-blocker, when and why? Acta Cardiology

2010 Oct65(5):565-70. doi: 10.2143/AC.65.5.2056244

PMID: 21125979 DOI: 10.2143/AC.65.5.2056244

ATC classification(2 codes)

ATC C07BA12

ATC C07AA12

Affected organisms(1)

Humans and other mammals

International brands(2)

Experimental properties(6)

External resources(3)

RxList PDRhealth Drugs.com

Commercial products(156)

Chemical identifiers

CAS, UNII, InChI Key and database cross-references

Show

Linked compound data from DrugBank Open Data (CC BY-NC 4.0)

Nadolol

DB01203

CAS number

42200-33-9

UNII (FDA)

FEN504330V

InChI Key (molecular fingerprint)

VWPOSFSPZNDTMJ-UCWKZMIHSA-N

Additional database identifiers

Drugs Product Database (DPD)

2099

ChEBI

7444

PubChem Compound

39147

PubChem Substance

46505509

KEGG Drug

D00432

ChemSpider

35815

BindingDB

25766

PharmGKB

PA450573

Therapeutic Targets Database

DAP000122

IUPHAR

554

Guide to Pharmacology

554

Wikipedia

Nadolol

ChEMBL

CHEMBL649

RxCUI

7226

HUGO Gene Nomenclature Committee (HGNC)

HGNC:285

GenAtlas

ADRB1

GeneCards

ADRB1

GenBank Gene Database

J03019

GenBank Protein Database

178200

IUPHAR

Guide to Pharmacology

UniProtKB

P08588

UniProt Accession

ADRB1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:286

GenAtlas

ADRB2

GeneCards

ADRB2

GenBank Gene Database

Y00106

GenBank Protein Database

29371

IUPHAR

Guide to Pharmacology

UniProtKB

P07550

UniProt Accession

ADRB2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:8498

GenAtlas

ORM1

GeneCards

ORM1

GenBank Gene Database

X02544

GenBank Protein Database

757907

UniProtKB

P02763

UniProt Accession

A1AG1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:8499

GeneCards

ORM2

GenBank Gene Database

BC015964

GenBank Protein Database

16359000

UniProtKB

P19652

UniProt Accession

A1AG2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:40

GenAtlas

ABCB1

GeneCards

ABCB1

GenBank Gene Database

M14758

GenBank Protein Database

307180

Guide to Pharmacology

768

UniProtKB

P08183

UniProt Accession

MDR1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:9212

GeneCards

POU2F1

UniProtKB

P14859

UniProt Accession

PO2F1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:9213

GeneCards

POU2F2

UniProtKB

P09086

UniProt Accession

PO2F2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:25588

GeneCards

SLC47A1

GenBank Gene Database

AK001709

GenBank Protein Database

7023138

Guide to Pharmacology

1216

UniProtKB

Q96FL8

UniProt Accession

S47A1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:26439

GeneCards

SLC47A2

Guide to Pharmacology

1217

UniProtKB

Q86VL8

UniProt Accession

S47A2_HUMAN

International reference pricing

16 formulations

Reference pricing from DrugBank. Prices are indicative and may not reflect current UK costs.

From $0.26/tablet

To $94.80/g

Apo-Nadol 40 mg Tablet

$0.26/tablet

Novo-Nadolol 40 mg Tablet

$0.26/tablet

Apo-Nadol 80 mg Tablet

$0.37/tablet

Novo-Nadolol 80 mg Tablet

$0.37/tablet

Nadolol 20 mg tablet

$0.92/tablet

Source: DrugBank. Used under CC BY-NC 4.0 academic licence for non-commercial purposes.

DrugBank citations

If you use DrugBank data in your research, please cite the following publications:

Knox C., Wilson M., Klinger C.M., et al

DrugBank 6.

0: the DrugBank Knowledgebase for 2024

Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275

PMID: 37953279

Wishart D.S., Feunang Y.D., Guo A.C., et al

DrugBank 5.

0: a major update to the DrugBank database for 2018

Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082

PMID: 29126136

Show earlier publications

Law V., Knox C., Djoumbou Y., et al

DrugBank 4.

0: shedding new light on drug metabolism

Nucleic Acids Res. 2014 Jan 142(1):D1091-7

PMID: 24203711

Knox C., Law V., Jewison T., et al

DrugBank 3.

0: a comprehensive resource for 'omics' research on drugs

Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41

PMID: 21059682

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a knowledgebase for drugs, drug actions and drug targets.

Nucleic Acids Research

2008 Jan36(Database issue):D901-6

PMID: 18048412

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a comprehensive resource for in silico drug discovery and exploration.

Nucleic Acids Research

2006 Jan 134(Database issue):D668-72

PMID: 16381955

Source: go.drugbank.comCC BY-NC 4.0

Updated 27 days ago(8 Mar 2026)

Back to medicines

Nadolol 10mg/5ml oral solution

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

WHO defined daily dose (DDD)

British National Formulary

Pharmacy stock checkers

Supply & product information

NHS UK identifiers

International identifiers

Browse tools

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Volume of distribution

Metabolism

Elimination

Clearance

Clinical essentials

Pharmacology

Deep science
9

Chemical identifiers

Nadolol

Additional database identifiers

International reference pricing

DrugBank citations

Nadolol 10mg/5ml oral solution

Safety & regulatory

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

Brand versions and licensed products

NHS reimbursement price

WHO defined daily dose (DDD)

Medicines like this

Prescribing statistics

Guidance (NICE / BNF)

British National Formulary

Availability, stocks & shortages

Pharmacy stock checkers

Supply & product information

Professional identifiers

NHS UK identifiers

International identifiers

Browse tools

Clinical trials

DrugBank data

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Volume of distribution

Metabolism

Elimination

Clearance

Clinical essentials

Pharmacology

Deep science9

Chemical identifiers

Nadolol

Additional database identifiers

International reference pricing

DrugBank citations

Deep science
9